{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:17:54Z","timestamp":1782785874931,"version":"3.54.5"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Tinnitus, a distressing condition that can significantly impair quality of life, has been associated with several medications, including triptans. This study aimed to explore the relationship between tinnitus and specific migraine treatments, focusing on triptans and calcitonin gene-related peptide (CGRP) inhibitors. Data from the FDA Adverse Event Reporting System (FAERS) through the third quarter of 2023 were analyzed to calculate proportional reporting ratios (PRR) and reporting odds ratios (ROR) for migraine treatments, specifically triptans and CGRP inhibitors. Positive tinnitus signals were identified when PRRs or RORs were greater than 2.0, the lower bound of the 95% confidence interval exceeded 1.0, and at least three cases were reported. Intra- and inter-class analyses were conducted to compare tinnitus reports among individual drugs and drug classes. Among 47,615 tinnitus-related adverse events, 345 were associated with CGRP inhibitors and 183 with triptans. Positive tinnitus signals were observed for several CGRP inhibitors, except eptinezumab and atogepant, and for all triptans except sumatriptan. Inter-class analysis revealed no significant differences between triptans and CGRP inhibitors. However, intra-class analysis identified naratriptan, almotriptan, and frovatriptan as having notable tinnitus signals among triptans, while CGRP inhibitors did not exhibit strong signals for any specific drug. Using real-world data from FAERS and pharmacovigilance methods, this study identified tinnitus signals related to migraine treatments, particularly among certain triptans. These findings provide preliminary evidence for further investigation into the relationship between migraine medications and tinnitus.<\/jats:p>","DOI":"10.1371\/journal.pone.0330493","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T17:26:59Z","timestamp":1755710819000},"page":"e0330493","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluating the association between migraine treatments and tinnitus: Insights from the US Food and Drug Administration adverse event reporting system"],"prefix":"10.1371","volume":"20","author":[{"given":"Yun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeabin","family":"Yook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-0837","authenticated-orcid":true,"given":"Su-jin","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"pone.0330493.ref001","article-title":"Clinical practice guideline: tinnitus","volume":"151","author":"DE Tunkel","year":"2014","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"5","key":"pone.0330493.ref002","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1044\/1092-4388(2005\/084)","article-title":"General review of tinnitus: prevalence, mechanisms, effects, and management","volume":"48","author":"JA Henry","year":"2005","journal-title":"J Speech Lang Hear Res"},{"key":"pone.0330493.ref003","first-page":"16","article-title":"Epidemiology of tinnitus.","volume-title":"Tinnitus: Theory and Management","author":"HJ Hoffman","year":"2004"},{"issue":"1","key":"pone.0330493.ref004","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2273.1994.tb01147.x","article-title":"Tinnitus and suicide","volume":"19","author":"JE Lewis","year":"1994","journal-title":"Clin Otolaryngol Allied Sci"},{"issue":"13","key":"pone.0330493.ref005","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1056\/NEJMcp1506631","article-title":"Tinnitus","volume":"378","author":"CA Bauer","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0330493.ref006","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.drudis.2009.11.003","article-title":"Pharmacological approaches to the treatment of tinnitus","volume":"15","author":"AB Elgoyhen","year":"2010","journal-title":"Drug Discov Today"},{"issue":"6","key":"pone.0330493.ref007","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/healthcare9060779","article-title":"Review of pharmacotherapy for tinnitus","volume":"9","author":"SH Kim","year":"2021","journal-title":"Healthcare (Basel)"},{"key":"pone.0330493.ref008","unstructured":"NIH \u2013 National Institute on Deafness and Other Communication Disorders (NIDCD) [Internet]. Tinnitus [cited 2024 Apr 8]. Available from: https:\/\/www.nidcd.nih.gov\/health\/tinnitus"},{"key":"pone.0330493.ref009","article-title":"Safety pharmacology and tinnitus.","author":"AJ. Szczepek","year":"2022","journal-title":"Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays. Cham; Springer"},{"key":"pone.0330493.ref010","unstructured":"Food and Drug Administration [Internet]. Amneal: Zomig (Zolmitriptan) package insert. 2018. [cited 2024 Apr 8]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020768s023,021231s014,021450s010lbl.pdf"},{"key":"pone.0330493.ref011","unstructured":"Food and Drug Administration [Internet]. Organon LLC: Maxalt (Rizatriptan Benzoate) package insert [cited 2024 Apr 8]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/020864s023,020865s024lbl.pdf"},{"key":"pone.0330493.ref012","unstructured":"Food and Drug Administration [Internet]. Janssen Pharms: Axert (Almotriptan Malate) package insert. 2017. [cited 2024 April 8]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021001s015lbl.pdf"},{"key":"pone.0330493.ref013","unstructured":"Food and Drug Administration [Internet]. Endo Pharms: Frova (Frovatriptan Succinate) package insert. [cited 2024 Apr 8]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021006s022lbl.pdf"},{"issue":"7","key":"pone.0330493.ref014","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/head.14153","article-title":"The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice","volume":"61","author":"J Ailani","year":"2021","journal-title":"Headache"},{"issue":"10","key":"pone.0330493.ref015","article-title":"Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis","volume":"4","author":"C-P Yang","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"pone.0330493.ref016","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40259-021-00469-8","article-title":"New insight on the safety of erenumab: an analysis of spontaneous reports of adverse events recorded in the US Food and Drug Administration adverse event reporting system database","volume":"35","author":"M Sessa","year":"2021","journal-title":"BioDrugs"},{"key":"pone.0330493.ref017","unstructured":"Food and Drug Administration [Internet]. Questions and Answers on FDA\u2019s Adverse Event Reporting System (FAERS). [cited 2024 Apr 8]. Available from https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers"},{"issue":"7","key":"pone.0330493.ref018","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"T Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"3","key":"pone.0330493.ref019","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4103\/0976-500X.162004","article-title":"International conference on harmonization of technical requirements for registration of pharmaceuticals for human use","volume":"6","author":"J Singh","year":"2015","journal-title":"J Pharmacol Pharmacother"},{"issue":"10","key":"pone.0330493.ref020","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/phar.2725","article-title":"Alopecia signals associated with calcitonin gene-related peptide inhibitors in the treatment or prophylaxis of migraine: a pharmacovigilance study","volume":"42","author":"RH Woods","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"3","key":"pone.0330493.ref021","first-page":"314","article-title":"Statistical and graphical approaches for disproportionality analysis of spontaneously-reported adverse events in pharmacovigilance","volume":"11","author":"RC Zink","year":"2013","journal-title":"Chin J Nat Med"},{"issue":"6","key":"pone.0330493.ref022","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"pone.0330493.ref023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"EP van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0330493.ref024","doi-asserted-by":"crossref","first-page":"797416","DOI":"10.1155\/2015\/797416","article-title":"Tinnitus and Headache","volume":"2015","author":"B Langguth","year":"2015","journal-title":"Biomed Res Int"},{"issue":"9","key":"pone.0330493.ref025","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/MAO.0000000000003247","article-title":"Tinnitus and subjective hearing loss are more common in migraine: a cross-sectional NHANES analysis","volume":"42","author":"K Goshtasbi","year":"2021","journal-title":"Otol Neurotol"},{"issue":"6","key":"pone.0330493.ref026","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/01.wnl.0000203647.48422.dd","article-title":"Basilar-type migraine: clinical, epidemiologic, and genetic features","volume":"66","author":"M Kirchmann","year":"2006","journal-title":"Neurology"},{"issue":"6","key":"pone.0330493.ref027","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/head.12845","article-title":"Association between headaches and tinnitus in young adults: cross-sectional study","volume":"56","author":"E Guichard","year":"2016","journal-title":"Headache"},{"issue":"8","key":"pone.0330493.ref028","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jamaoto.2018.0939","article-title":"Association of tinnitus and other cochlear disorders with a history of migraines","volume":"144","author":"J-H Hwang","year":"2018","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"4","key":"pone.0330493.ref029","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/lio2.1109","article-title":"Migraine management for the otolaryngologist","volume":"8","author":"KA Brooks","year":"2023","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"2","key":"pone.0330493.ref030","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s13311-017-0592-1","article-title":"Migraine treatment: current acute medications and their potential mechanisms of action","volume":"15","author":"JJY Ong","year":"2018","journal-title":"Neurotherapeutics"},{"key":"pone.0330493.ref031","article-title":"Acute treatment of migraine in adults.","volume-title":"UptoDate","author":"TJ Schwedt"},{"issue":"4","key":"pone.0330493.ref032","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/0333102413508661","article-title":"Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis","volume":"34","author":"K Thorlund","year":"2014","journal-title":"Cephalalgia"},{"issue":"9294","key":"pone.0330493.ref033","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","article-title":"Oral triptans (serotonin 5-HT(1B\/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials","volume":"358","author":"MD Ferrari","year":"2001","journal-title":"Lancet"},{"issue":"5659","key":"pone.0330493.ref034","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1136\/bmj.2.5659.766","article-title":"Tinnitus and propranolol","volume":"2","author":"RH Mostyn","year":"1969","journal-title":"Br Med J"},{"issue":"1","key":"pone.0330493.ref035","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1808-8694(15)31297-0","article-title":"Pulsatile tinnitus: treatment with clonazepam and propranolol","volume":"71","author":"S Albertino","year":"2005","journal-title":"Braz J Otorhinolaryngol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T17:27:04Z","timestamp":1755710824000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330493"}},"subtitle":[],"editor":[{"given":"Hantong","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330493","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]}}}